Dr. Reddy's in pact with Rheoscience

HYDERABAD: Dr. Reddy's Laboratories has entered into a co-development and commercialisation agreement with Denmark-based Rheoscience A/S for the joint development and commercialisation of balaglitazone (DRF 2593), a partial PPAR-gamma agonist for the treatment of type 2 diabetes. Under the agreement, Rheoscience will fund all the costs associated with the Phase III clinical trials of DRF 2593 and Dr. Reddy's will pay Rheoscience a pre-determined amount towards its share of the development costs.

Recommended for you